In a large systemic review of 169 MG patients who received Rituximab, remission (PR or CSR) and MM was achieved in 72% of MuSK-MG patients in contrast to 30% of AChR-MG patients, with post-treatment relapses being markedly reduced in the MuSK-MG cohort (118). Here, MUSK is linked to myasthenia gravis.